Prevention of doxorubicin-induced hematotoxicity in mice by interleukin 1.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Cancer Research

• Publication date

  1989-07-15

• Fields of study

  Medicine

• Identifiers
  PMID 2786748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The mouse as a model for predicting the myelosuppressive effects of anticancer drugs

  2004cited by this paper
• The influence of IL-1 treatment on the reconstitution of the hemopoietic and immune systems after sublethal radiation.

  1988influential reference
• Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models.

  1988cited by this paper
• Interleukin-1 enhances murine granulopoiesis in vivo.

  1988cited by this paper
• Monoclonal antibodies to human recombinant interleukin 1 (IL 1)beta: quantitation of IL 1 beta and inhibition of biological activity.

  1987cited by this paper
• Inhibition by interleukin‐1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias

  1987cited by this paper
• Interleukin 1 induces cultured human endothelial cell production of granulocyte-macrophage colony-stimulating factor.

  1987cited by this paper
• Regulation of early human hematopoietic (BFU-E and CFU-GEMM) progenitor cells in vitro by interleukin 1-induced fibroblast-conditioned medium.

  1987cited by this paper
• Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice.

  1987influential reference
• Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model.

  1987cited by this paper
• Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1.

  1987cited by this paper
• Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes.

  1987cited by this paper
• Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

  1987cited by this paper
• Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias.

  1987cited by this paper
• Cytokines in radioprotection. Comparison of the radioprotective effects of IL-1 to IL-2, GM-CSF and IFN gamma.

  1986cited by this paper
• Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells.

  1986cited by this paper
• Interleukin 1 is a radioprotector.

  1986cited by this paper
• Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF

  1986cited by this paper
• Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1.

  1986cited by this paper
• Interleukin 1 as a cytokine inducer.

  1986cited by this paper
• Granulocyte-macrophage colony-stimulating factors

  1985cited by this paper
• Granulocyte-macrophage colony-stimulating factors

  1985cited by this paper
• Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin.

  1985cited by this paper
• The Numerous Postulated Biological Manifestations of Interleukin‐1

  1984cited by this paper
• Granulocytopenia and cancer therapy: Past problems, current solutions, future challenges

  1984cited by this paper
• Interleukin-1 and the pathogenesis of the acute-phase response.

  1984cited by this paper
• Ionizing radiation and the immune response.

  1976cited by this paper

• The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin-induced cardiotoxicity

  2020cites this paper
• Taraxacum Officinale (Dandelion) Roots Extract Mitigates Doxorubicin-Induced HematoCardiotoxicity in Male Albino Rats

  2019cites this paper
• The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats

  2018cites this paper
• Nanoparticle‐Laden Macrophages for Tumor‐Tropic Drug Delivery

  2018cites this paper
• Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.

  2015cites this paper
• Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1-Based Studies of Hematopoietic Reconstitution

  2014cites this paper
• Effect of Oral Administration of Chloramphenicol on Hematological Profile of Male Charles Foster Rats

  2013cites this paper
• Targeted core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.

  2010cites this paper
• Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.

  2010cites this paper
• Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity.

  2005cites this paper
• Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells

  2003cites this paper
• Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemother

  2001cites this paper
• Interleukin 1 alpha (IL-1) and macrophage colony-stimulating factor (M-CSF) accelerate recovery from multiple drug-induced myelosuppression.

  1998cites this paper
• Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors.

  1997cites this paper
• Radio- and chemoprotection of bone marrow cells by opposite cell cycle-acting cytokines.

  1997cites this paper
• Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940.

  1997cites this paper
• Phase 1 Trial of Recombinant Human Interleukin-1β (rhIL-1β), Carboplatin, and Etoposide in Patients with Solid Cancers: Southwest Oncology Group Study 8940

  1997cites this paper
• Phase I trial of subcutaneous interleukin‐1α in children with malignant solid tumors

  1997cites this paper
• Sensitization by interleukin‐lα of carboplatinum anti‐tumor activity against human ovarian (NIH:OVCAR‐3) carcinoma cells in vitro and in vivo

  1996cites this paper
• Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo.

  1996cites this paper
• Protective effects of human interleukin-1 on hematopoietic progenitor cells from L-phenylalanine mustard.

  1995cites this paper
• The effects of interleukin-1 beta and tumor necrosis factor-alpha on in vitro colony formation by human hematopoietic progenitor cells exposed to doxorubicin or hydroquinone.

  1995cites this paper
• WR-1065 as a chemoprotector in Adriamycin chemotherapy.

  1994cites this paper
• Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3).

  1993cites this paper
• Chemotherapy-Induced Alopecia: New Developments

  1993cites this paper
• The comparative effects of IL-1 and TNF on AMN-anti-Ly 2.1 immunoconjugate therapy

  1993cites this paper
• Synergistic antiproliferative effects of interleukin-1α and doxorubicin against the human ovarian carcinoma cell line (NIH : OVCAR-3)

  1993cites this paper
• Tumor inhibition and hematopoietic stimulation in mice by a synthetic copper‐ATP complex

  1993cites this paper
• Interleukin 1β improves survival following cecal ligation and puncture

  1992cites this paper
• Effects of granulocyte colony-stimulating factor, interleukin-1 alpha, and interleukin-6 on prolonged myelosuppression induced by nimustine hydrochloride in rats.

  1992cites this paper
• Interleukin 1 beta improves survival following cecal ligation and puncture.

  1992cites this paper
• The therapeutic potential of interleukin-1 and tumor necrosis factor on hematopoietic stem cells.

  1992cites this paper
• Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.

  1992cites this paper
• Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it?

  1992cites this paper
• Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.

  1991cites this paper
• Leukocytosis in mice following long-term reconstitution with genetically-modified bone marrow cells constitutively expressing interleukin 1 alpha or interleukin 6.

  1991cites this paper
• Biological effects and possible clinical applications of interleukin 1.

  1991cites this paper
• Interleukin-1: biology, pathophysiology, and clinical prospects.

  1990cites this paper
• Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.

  1990cites this paper
• Interleukin-1-α as a Modulator of Cytotoxic Drug Activity Against Human Cancer Cells

  1990cites this paper